Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNPAT | O15228 | 1/20 | 0.57 |
| ▸ | FOLH1 | Q04609 | 5/20 | 0.52 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.52 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.52 |
| ▸ | NOD1 | Q9Y239 | 5/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7046058 | 1.00 | GNPAT (0.57) | GNPATFOLH1RIMKLANAALAD2NOD1 | |
| SCHEMBL7045832 | 0.97 | GNPAT (0.57) | GNPATFOLH1RIMKLANAALAD2NOD1 | |
| SCHEMBL7042608 | 0.95 | NOD1 (0.58) | GNPATFOLH1RIMKLANAALAD2NOD1 | |
| SCHEMBL7602122 | 0.95 | NOD1 (0.58) | GNPATFOLH1RIMKLANAALAD2NOD1 | |
| SCHEMBL7602113 | 0.95 | NOD1 (0.58) | GNPATFOLH1RIMKLANAALAD2NOD1 | |
| SCHEMBL24805419 | 0.95 | NOD1 (0.58) | GNPATFOLH1RIMKLANAALAD2NOD1 | |
| SCHEMBL6889134 | 0.95 | NOD1 (0.58) | GNPATFOLH1RIMKLANAALAD2NOD1 | |
| SCHEMBL8054833 | 0.95 | NOD1 (0.58) | GNPATFOLH1RIMKLANAALAD2NOD1 | |
| SCHEMBL13202423 | 0.95 | NOD1 (0.58) | GNPATFOLH1RIMKLANAALAD2NOD1 | |
| SCHEMBL7044786 | 0.95 | NOD1 (0.58) | GNPATFOLH1RIMKLANAALAD2NOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11351151-B2 | Compound having anticancer activity and preparation method and application | 3D MEDICINES (BEIJING) CO., LTD. (CN) | 2022-06-07 | — | — | US | disclosed |
| EP-3542796-A1 | COMPOUND HAVING ANTI-CANCER EFFECT, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 3D Medicines (Beijing) Co., Ltd. (CN) | 2019-09-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11351151-B2 | Compound having anticancer activity and preparation method and application | HDGF, MKI67, LITAF | GNPAT 2333/4885FOLH1 990/4885RIMKLA 4577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.